Navigation Links
Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
Date:8/8/2012

LONDON, Aug. 8, 2012 /PRNewswire/ -- Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED). BED is a psychiatric condition that is manifested by recurrent episodes of eating unusually large amounts of food in a short period of time associated with a sense of lack of control over food intake.

BED is a major cause of obesity for those patients with addictive behavior towards food. It is the most chronic and common of all eating disorders with a significant cost to society, with 12 to 18 million people in the United States likely meeting the criteria for BED and a further 20 million people exhibiting bingeing behavior. It is significantly undertreated with no approved pharmacological therapies.

Patients receiving the naloxone nasal spray achieved the study's primary endpoint by exhibiting a statistically significant reduction in time spent per week binge eating compared to those patients who received a placebo nasal spray, reducing their bingeing by 125 minutes per week compared to 84 minutes per week for placebo-treated subjects (p=0.024).

The effect of the naloxone nasal spray was especially pronounced when comparing the baseline bingeing with the level of bingeing during the last week of treatment, with the patients receiving naloxone reducing their bingeing by 158 minutes per week compared to 101 minutes per week for placebo-treated subjects (p=0.018) during this period. Overall, 81% of patients completed the entire six-month study with no statistically significant difference in dropout rates between the placebo and the treatment groups and without any Serious Adverse Events (SAE) reported during the trial.
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
2. Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team
3. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
4. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
5. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
6. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
7. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
8. Juventas Therapeutics Raises $22.2 Million Series B Financing
9. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
10. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
11. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... to materialise. Yet, scientists are making progress in ... One such approach relies on quantum dotsa kind ... electric field. A new study demonstrates that changing ... (TQDs) with electrical impulses can help better control ... be used as quantum information units, which would ...
(Date:7/24/2014)... natural and synthetic processes prefer to settle into ... energyit is within the realm of non-equilibrium conditions ... changes in energy and phases, such as temperature ... allow humans to regulate their body temperature, airplanes ... seismic activity. , But even though these ...
(Date:7/24/2014)... -- Research and Markets has announced the ... Instruments Market 2014-2018" report to their offering. ... is the study of the gene and its functions ... functions of proteomes or sets of proteins by using ... the mapping of genes and DNA sequencing to understand ...
(Date:7/24/2014)... 24, 2014 SRI International has been awarded ... Institute of Allergy and Infectious Diseases (NIAID), part of ... of potential therapies for HIV infection and AIDS. The ... and AIDS and the complications and opportunistic infections associated ... sexual transmission of HIV. According to ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... are viewed as an enabler of increased research output at ... says he is making a pitch to investors to help ... side Milwaukee campus. , ,Santiago wants separate campuses for the ... and teaching, and he wants them in the proximity of ...
... - In its second acquisition of the past ... the Green Bay operations of Bedrock Managed Services & ... Milwaukee-based provider of information technology services, to establish a ... said it will maintain Bedrock's Green Bay office and ...
... Strategene Corp . will pay Third Wave Technologies ... of their patent dispute, and they have agreed to a ... ,The case, which was litigated in U.S. District Court for ... to the Federal Circuit in Washington, D.C., involves two companies ...
Cached Biology Technology:
(Date:7/24/2014)... affect the connections between nerve cells and influence the ... of the brain that plays a significant role in ... of the study have been published in the journal ... active communication between nerve cells, known as neurons. For ... network where they constantly relay signals to one another. ...
(Date:7/24/2014)... in the United States, wildland managers often utilize the ... trees (ladder fuels). These cuttings and other post-logging ... danger in order to dispose of the material. To ... often cover all or part of the debris pile ... plastic, in order to keep water out. A recent ...
(Date:7/24/2014)... Neiker-Tecnalia is currently conducting research into the potato genes ... characterised by a reduction in rainfall and increased extremes ... the most resistant genes in order to create new ... conditions.The research is also seeking to find out how ... of greater drought and higher and lower temperatures. , ...
Breaking Biology News(10 mins):A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4Study gives new perspective on agricultural plastic, debris burning, and air quality 2Neiker-Tecnalia is researching the potato genes that best adapt to climate change 2
... Office of Naval Research (ONR) today launched a collaborative ... cellspart of a larger effort to use the smallest ... their missions. ONR currently has multiple ongoing projects ... tools and methods for creating new organisms with specific ...
... National Institutes of Health has awarded Dr. Daniel Geschwind, director ... five-year, $10 million grant to continue his research on the ... investigations to include the genetics of autism in African Americans. ... collaborative work by Geschwind and experts at other autism centers ...
... described small genetic changes that enable the H5N1 bird flu ... So far there have only been isolated cases of ... H5N1 virus can,t replicate efficiently in the nose. The new ... of controversial research published in 2012 which demonstrated that just ...
Cached Biology News:Recruiting engineered cells to work for warfighters 2Recruiting engineered cells to work for warfighters 3Autism in black and white: NIH grant helps scientist study disorder in African Americans 2Bird flu mutation study offers vaccine clue 2
... Zero Background Cloning Kit includes the pZErO-1 ... E. coli. The pZErO-1 vector utilizes positive ... size of the Zeocin resistance gene reduces ... and transformation efficiencies. The kit contains all ...
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
Request Info...
... S-Adenosyl-Homocysteine. S-Adenosyl Homocysteine 100%,S-Adenosyl Methionine 2.5%,Adenosine ... 0.27%,Homocysteine ... <0.1%,L-Cysteine ... Assay Range: 0.1 ug/ml to 1 ...
Biology Products: